Penumbra, Inc. (PEN)
USD 238.9
(-3.49%)
USD 238.9
(-3.49%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 73.55 Million USD | 503.26% |
| 2022 | -18.23 Million USD | -143.15% |
| 2021 | -7.5 Million USD | 80.74% |
| 2020 | -38.94 Million USD | -181.97% |
| 2019 | 47.5 Million USD | 5676.06% |
| 2018 | -852 Thousand USD | -173.13% |
| 2017 | 1.16 Million USD | 186.3% |
| 2016 | -1.35 Million USD | -132.3% |
| 2015 | 4.17 Million USD | 38.88% |
| 2014 | 3 Million USD | 367.23% |
| 2013 | -1.12 Million USD | -132.85% |
| 2012 | 3.42 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 12.1 Million USD | -65.45% |
| 2024 Q3 | 35.36 Million USD | 980.58% |
| 2024 Q2 | -4.01 Million USD | -133.19% |
| 2023 Q1 | 1.43 Million USD | 189.12% |
| 2023 Q2 | 17.88 Million USD | 1148.36% |
| 2023 Q4 | 35.02 Million USD | 177.46% |
| 2023 Q3 | 12.62 Million USD | -29.43% |
| 2023 FY | 73.55 Million USD | 503.26% |
| 2022 Q3 | 5.43 Million USD | 4009.35% |
| 2022 Q4 | -1.6 Million USD | -129.59% |
| 2022 FY | -18.23 Million USD | -143.15% |
| 2022 Q1 | -4.04 Million USD | 89.9% |
| 2022 Q2 | -139 Thousand USD | 96.56% |
| 2021 Q1 | 13.46 Million USD | 871.52% |
| 2021 Q2 | 10.31 Million USD | -23.4% |
| 2021 Q3 | 8.78 Million USD | -14.85% |
| 2021 FY | -7.5 Million USD | 80.74% |
| 2021 Q4 | -40.05 Million USD | -556.18% |
| 2020 Q2 | -17.64 Million USD | -2993.28% |
| 2020 FY | -38.94 Million USD | -181.97% |
| 2020 Q4 | -1.74 Million USD | 91.34% |
| 2020 Q3 | -20.15 Million USD | -14.22% |
| 2020 Q1 | 610 Thousand USD | -94.23% |
| 2019 Q4 | 10.57 Million USD | -18.47% |
| 2019 Q3 | 12.97 Million USD | 1.37% |
| 2019 Q2 | 12.8 Million USD | 14.79% |
| 2019 Q1 | 11.15 Million USD | 67.22% |
| 2019 FY | 47.5 Million USD | 5676.06% |
| 2018 Q4 | 6.66 Million USD | 131.99% |
| 2018 Q2 | 9.28 Million USD | 129.49% |
| 2018 Q1 | 4.04 Million USD | 4.9% |
| 2018 FY | -852 Thousand USD | -173.13% |
| 2018 Q3 | -20.84 Million USD | -324.59% |
| 2017 FY | 1.16 Million USD | 186.3% |
| 2017 Q4 | 3.85 Million USD | 464.57% |
| 2017 Q3 | 683 Thousand USD | 151.43% |
| 2017 Q2 | -1.32 Million USD | 35.09% |
| 2017 Q1 | -2.04 Million USD | -77.6% |
| 2016 Q3 | -1.36 Million USD | -103.43% |
| 2016 Q1 | 1.83 Million USD | 0.82% |
| 2016 Q2 | -670 Thousand USD | -136.51% |
| 2016 Q4 | -1.15 Million USD | 15.48% |
| 2016 FY | -1.35 Million USD | -132.3% |
| 2015 Q1 | 3.99 Million USD | 1139.13% |
| 2015 FY | 4.17 Million USD | 38.88% |
| 2015 Q4 | 1.82 Million USD | -16.59% |
| 2015 Q3 | 2.18 Million USD | 157.23% |
| 2015 Q2 | -3.81 Million USD | -195.56% |
| 2014 Q4 | 322 Thousand USD | 3.54% |
| 2014 Q2 | 535 Thousand USD | -70.94% |
| 2014 FY | 3 Million USD | 367.23% |
| 2014 Q3 | 311 Thousand USD | -41.87% |
| 2014 Q1 | 1.84 Million USD | 0.0% |
| 2013 FY | -1.12 Million USD | -132.85% |
| 2012 FY | 3.42 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Abbott Laboratories | 6.47 Billion USD | 98.865% |
| Allurion Technologies Inc. | -78.07 Million USD | 194.202% |
| Artivion, Inc. | 5.74 Million USD | -1180.93% |
| Avanos Medical, Inc. | 4.2 Million USD | -1651.214% |
| Butterfly Network, Inc. | -145.61 Million USD | 150.512% |
| Butterfly Network, Inc. | -145.61 Million USD | 150.512% |
| Bio-Rad Laboratories, Inc. | 383.79 Million USD | 80.836% |
| Boston Scientific Corporation | 2.34 Billion USD | 96.861% |
| Perspective Therapeutics, Inc. | -15.18 Million USD | 584.462% |
| CONMED Corporation | 130.78 Million USD | 43.762% |
| Edwards Lifesciences Corporation | 1.53 Billion USD | 95.206% |
| Paragon 28, Inc. | -37.3 Million USD | 297.14% |
| Glaukos Corporation | -128.7 Million USD | 157.149% |
| Globus Medical, Inc. | 133.14 Million USD | 44.757% |
| Inspire Medical Systems, Inc. | -40.27 Million USD | 282.64% |
| Integer Holdings Corporation | 167.33 Million USD | 56.044% |
| Medtronic plc | 5.14 Billion USD | 98.57% |
| Nevro Corp. | -99.3 Million USD | 174.064% |
| Owlet, Inc. | -28.63 Million USD | 356.884% |
| Vicarious Surgical Inc. | -80.66 Million USD | 191.18% |
| Smith & Nephew plc | 425 Million USD | 82.694% |
| Sonendo, Inc. | -57.74 Million USD | 227.376% |
| STERIS plc | 836.11 Million USD | 91.203% |
| Stryker Corporation | 3.88 Billion USD | 98.108% |
| Vapotherm, Inc. | -39.08 Million USD | 288.206% |
| Zimmer Biomet Holdings, Inc. | 1.27 Billion USD | 94.243% |